Impact of body size on platelet function in patients with acute coronary syndrome on dual antiplatelet therapy

Abstract Introduction: Patients undergoing acute percutaneous coronary intervention receive dual antiplatelet therapy for secondary prevention. Recurrent myocardial infarction or bleedings are possibly due to under- or overdosing of antiplatelet therapy in relation to body size. Methods: We correlated residual platelet aggregation with body mass index, body surface area, lean body mass and blood volume in 220 patients on prasugrel (n = 121) or ticagrelor (n = 99). Results: Platelet aggregation outside the recommended window was recorded in 85 patients, but not correlated with any of the body indices. Conclusion: Body size does not affect platelet response to prasugrel or ticagrelor at the guideline-recommended fixed dosages. Vascul Pharmacol. 2022 Jul 20;107089. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.